GlassScriptPhysician profile
Jeffrey A Langbein
NPI 1134109796
$2,091.13
in general payments reported to CMS, 2019-2025
28 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $153 · 2021: $16.56 · 2022: $518 · 2023: $329 · 2024: $252 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.79 | 2019-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $165.98 | 2019-2023 | |
| Lilly USA, LLC | $165.23 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $146.23 | 2019-2025 | Otezla |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Novo Nordisk INC | $121.99 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Biotech, INC. | $120.80 | 2025 | Simponi Aria, Tremfya |
| Merck Sharp & Dohme LLC | $117.83 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.18 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $105.39 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $104.24 | 2019-2022 | |
| Daiichi Sankyo INC. | $85.99 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $80.66 | 2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.22 | 2022-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $56.12 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $54.95 | 2021-2022 | |
| Amarin Pharma, INC. | $53.11 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.78 | 2019-2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $22.98 | 2022 | |
| Ibsa Pharma INC. | $22.94 | 2019 | |
| Edwards Lifesciences Corporation | $20.09 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2023 | Trintellix |
| Theratechnologies INC. | $13.77 | 2019 | |
| Exact Sciences Corporation | $13.71 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $13.20 | 2023 | Nexletol |
| Dynavax Technologies Corporation | $8.70 | 2023 | Heplisav-B |
| Intra-Sana Laboratories | $7.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Langbein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.